Weight regain after stopping semaglutide is possible and common , especially if old habits return
Several patient-specific and medication-related factors can elevate the risk of hypoglycemia in individuals taking tirzepatide
[20] In a 1987 nomination document for the National Register of Historic Places, proponents cited Gilbert & Bennett as an "anachronism" in the history of U.S
Among these potential key players, Roche continues to stand out with multiple obesity candidates within its pipeline, all in phase II trials (as of November 2025), and it is expected to enter the market in 2029 or later
Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS